Indeed, immune checkpoint blockade (ICB) therapy targeting PD-1 and CTLA-4 pathways, often in combination as dual immune checkpoint blockade (DICB) therapy, has revolutionized the treatments of cancers including melanoma, non-small cell lung cancer, and bladder cancer (2, 3). This evidence concerns the gene CTLA4 and melanoma.